RxDoctor Payments DataLook up a doctor →

Isaac Biney, MD

Pulmonary Disease · Knoxville, TNNPI 1780939751

Payments from drug & device makers

$73,029in general payments, 2019–2025

Across 433 payments — averaging $168.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe Farmaceutici S.p.a.$57K
  • Mylan Specialty L.p.$4K
  • Intuitive Surgical$3K
  • GSK$1K
  • Viatris Specialty LLC$1K
  • Boehringer Ingelheim$998
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$3,71423%
  • Travel & lodging$1,0066%
  • Food & beverage$8,53552%
  • Education$3,18819%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,029 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$83,580
Medicare patients
360
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate30$373,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter109$90,632
Breo ElliptaFluticasone/Vilanterol58$26,439
Spiriva RespimatTiotropium Bromide15$12,208
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$12,047
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$10,763
SymbicortBudesonide/Formoterol Fumarate18$5,840
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$3,857
Albuterol Sulfate HfaAlbuterol Sulfate117$2,565
Roflumilast13$1,935
Mycophenolate Mofetil13$1,637
Prednisone61$301
Montelukast Sodium30$291
Azithromycin19$241
Fluticasone Propionate15$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$998$396,55161 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,054$129,118191 claims
AstraZenecaSymbicort$840$5,84018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.

Other pulmonary disease in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →